Natural History Of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study In The United States
dc.contributor.author | Al-Shamsi, Humaid O. | |
dc.contributor.author | Abdel-Wahab, Reham | |
dc.contributor.author | Hassan, Manal M. | |
dc.contributor.author | Shalaby, Ahmed S. | |
dc.contributor.author | Dahbour, Ibrahim | |
dc.contributor.author | Lacin, Sahin | |
dc.contributor.author | Mahvash, Armeen | |
dc.contributor.author | Odisio, Bruno C. | |
dc.contributor.author | Murthy, Ravi | |
dc.contributor.author | Avritscher, Rony | |
dc.contributor.author | Abdelsalam, Mohamed E. | |
dc.contributor.author | Rashid, Asif | |
dc.contributor.author | Vauthey, Jean-Nicolas | |
dc.contributor.author | Aloia, Thomas A. | |
dc.contributor.author | Conrad, Claudius | |
dc.contributor.author | Chun, Yun Shin | |
dc.contributor.author | Krishnan, Sunil | |
dc.contributor.author | Das, Prajnan | |
dc.contributor.author | Koay, Eugene J. | |
dc.contributor.author | Amin, Hesham M. | |
dc.contributor.author | Yao, James C. | |
dc.contributor.author | Kaseb, Ahmed O. | |
dc.date.accessioned | 2019-12-10T11:15:18Z | |
dc.date.available | 2019-12-10T11:15:18Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 0030-2414 | |
dc.identifier.uri | https://doi.org/10.1159/000455957 | |
dc.identifier.uri | http://hdl.handle.net/11655/15206 | |
dc.description.abstract | Background: Hepatocellular carcinoma (HCC) prognosis depends on clinicopathological features in addition to the treatment provided. We aimed to assess the natural history of TNM stage I HCC tumors which received different treatment over a period of 20 years. Methods: Between 1992 and 2011, a total of 397 stage I HCC patients were included. Detailed information was retrieved from MD Anderson Cancer Center patients' medical records. The Kaplan-Meier method was used to calculate patients' overall survival (OS). Cox regression analysis was used to calculate the estimated hazard ratio and 95% confidence interval of different prognostic factors. Results: Out of 397 patients, 67.5% were males, 42.8% had hepatitis-related HCC, and 59.7% had underlying cirrhosis. After adjustment for confounding factors, we found that all therapeutic modalities were associated with a significant mortality rate reduction with an OS of 63, 42.03, 34.3, and 22.1 months among patients treated with surgery, ablation, local, and systemic therapy, respectively. A restricted analysis of cirrhotic and noncirrhotic patients showed that ablative and local therapy were significantly associated with a longer OS compared to systemic therapy. Conclusion: TNM stage I HCC patients have a favorable prognosis regardless of the type of treatment. Notably, ablative and local therapy significantly improved OS compared to systemic therapy. (C) 2017 S. Karger AG, Basel | |
dc.language.iso | en | |
dc.publisher | Karger | |
dc.relation.isversionof | 10.1159/000455957 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Oncology | |
dc.title | Natural History Of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study In The United States | |
dc.type | info:eu-repo/semantics/article | |
dc.relation.journal | Oncology | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 93 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 233 | |
dc.identifier.endpage | 242 | |
dc.description.index | WoS |